[FBIO] Fortress Biotech, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.37 Change: 0.15 (6.76%)
Ext. hours: Change: 0 (0%)

chart FBIO

Refresh chart

Strongest Trends Summary For FBIO

FBIO is in the medium-term down -15% below S&P in 4 months. In the long-term down -65% below S&P in 2 years and down -95% below S&P in 10 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities9.36 M Cash From Investing Activities-1.36 M Cash From Operating Activities-8.83 M Gross Profit
Net Profit-12.06 M Operating Profit-12.07 M Total Assets90.45 M Total Current Assets69.61 M
Total Current Liabilities5.93 M Total Debt24.01 M Total Liabilities30.3 M Total Revenue500 K
Technical Data
High 52 week3.83 Low 52 week0.57 Last close1.9 Last change-1.55%
RSI62.9 Average true range0.19 Beta1.26 Volume144.58 K
Simple moving average 20 days10.34% Simple moving average 50 days7.61% Simple moving average 200 days22.1%
Performance Data
Performance Week6.74% Performance Month30.14% Performance Quart-12.84% Performance Half71.17%
Performance Year-47.8% Performance Year-to-date120.93% Volatility daily6.73% Volatility weekly15.06%
Volatility monthly30.86% Volatility yearly106.89% Relative Volume321.39% Average Volume784.81 K
New High New Low

News

2019-06-03 07:00:00 | Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain

2019-05-23 08:30:00 | Mustang Bio and St. Jude Children’s Research Hospital to Participate in Panel Discussion at Boston CEO 2019

2019-05-17 09:35:01 | Will Fortress Biotech to Surge Higher?

2019-05-16 08:00:00 | Mustang Bio and Nationwide Children’s Hospital Receive Orphan Drug Designation for MB-108 Oncolytic Virus C134 for the Treatment of Malignant Glioma

2019-05-13 08:00:00 | Mustang Bio to Present at the Cell & Gene Therapy USA Congress 2019

2019-05-13 07:30:00 | Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights

2019-05-10 07:44:32 | Fortress Biotech: 1Q Earnings Snapshot

2019-05-10 07:30:00 | Fortress Biotech Reports First Quarter 2019 Financial Results and Recent Corporate Highlights

2019-05-09 17:00:00 | Checkpoint Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights

2019-05-08 09:25:00 | Mustang Bio Announces Full Exercise of Option

2019-05-08 07:30:00 | Mustang Bio Announces City of Hope Opens First-of-Its-Kind Multiple Myeloma CAR T Cell Therapy Trial Targeting CS1 Protein

2019-05-01 07:30:00 | Checkpoint Therapeutics Announces Positive Interim Clinical Results of Anti-PD-L1 Antibody Cosibelimab

2019-04-30 07:30:00 | Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors

2019-04-29 16:01:00 | Mustang Bio Announces Proposed Public Offering of Common Stock

2019-04-29 09:07:24 | What Kind Of Shareholders Own Fortress Biotech, Inc. NASDAQ:FBIO?

2019-04-23 05:00:10 | Is Mustang Bio the Next Great Biotech Stock?

2019-04-17 19:16:26 | Mustang Bio Soars 485% After Its Novel Gene Therapy Cured ‘Bubble Boys’

2019-04-17 17:01:00 | St. Jude Children’s Research Hospital publishes results of Lentiviral Gene Therapy for Treatment of Infants with X-linked Severe Combined Immunodeficiency in New England Journal of Medicine

2019-04-09 08:30:00 | Mustang Bio to Present at the World Orphan Drug Congress USA 2019

2019-04-01 09:00:00 | Mustang Bio Announces $20 Million Venture Debt Financing Agreement with Horizon Technology Finance

2019-03-18 07:30:00 | Mustang Bio Reports Full-Year 2018 Financial Results and Recent Corporate Highlights

2019-03-18 07:30:00 | Fortress Biotech Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Corporate Highlights

2019-03-14 10:42:02 | All You Need to Know About Fortress Biotech FBIO Rating Upgrade to Strong Buy

2019-03-13 08:30:00 | Mustang Bio to Present at Oppenheimer’s 29th Annual Healthcare Conference

2019-03-12 07:30:00 | Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights

2019-02-28 08:41:01 | Sarepta SRPT Jumps: Stock Rises 8.3%

2019-02-20 08:30:00 | Mustang Bio and Nationwide Children’s Hospital Enter into Exclusive Worldwide License Agreement for Oncolytic Virus C134 to Treat Glioblastoma Multiforme

2019-02-12 09:00:00 | Fortress Biotech Completes Final Stage Closing of the Sale of its Remaining Shares of National Holdings Corporation

2019-02-11 07:30:00 | Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen a Cipla subsidiary

2019-02-05 10:30:00 | Biotech on the Brink of Breaking Out

2019-02-01 08:35:00 | Fortress BioTech, Late Stage Development Progress and Caelum Partnership with Alexion

2019-02-01 08:30:00 | Biotechs to Put on Your Watchlist

2019-01-31 09:20:00 | 4 Biotech Stocks Making Moves On Thursday 1/31/19

2019-01-31 06:30:00 | Fortress Biotech Announces CAEL-101 Strategic Partnership with Alexion Pharmaceuticals

2019-01-28 10:05:00 | ATXI: How Much Are CVRs Worth?

2019-01-27 08:10:35 | Have Insiders Been Selling Fortress Biotech, Inc. NASDAQ:FBIO Shares?

2019-01-02 07:20:00 | Report: Exploring Fundamental Drivers Behind Energy Transfer LP, Cable One, DTE Energy, Civitas Solutions, Owens Realty Mortgage, and Fortress Biotech — New Horizons, Emerging Trends, and Upcoming Developments

2018-12-21 13:17:18 | Fortress Biotech Recaps Corporate Highlights and Achievements in 2018

2018-12-20 08:30:00 | Mustang Bio Receives Orphan Drug Designation for MB-102 CD123 CAR T for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

2018-12-19 08:00:00 | Avenue Therapeutics Announces Dosing of First Patient in Second Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain

2018-12-12 14:58:17 | Should You Worry About Fortress Biotech, Inc.’s NASDAQ:FBIO CEO Pay?

2018-11-20 08:37:01 | Fortress Biotech FBIO in Focus: Stock Moves 6.5% Higher

2018-11-19 08:00:00 | B. Riley Financial Enters a Definitive Agreement to Purchase Fortress Biotech’s Stake in National Holdings Corporation

2018-11-19 08:00:00 | Fortress Biotech Announces Agreement to Sell Its Majority Stake in National Holdings Corporation to NHC Holdings, LLC, a wholly-owned subsidiary of B. Riley Financial

2018-11-19 08:00:00 | B. Riley Financial Enters Agreement to Purchase Fortress Biotech’s Stake in National Holdings

2018-11-14 08:20:00 | Consolidated Research: 2018 Summary Expectations for Franco-Nevada, CPS Technologies, I.D., Fortress Biotech, Avalon, and Key Tronic — Fundamental Analysis, Key Performance Indications

2018-11-13 06:30:00 | InvaGen a Cipla subsidiary Announces Acquisition Agreement with Avenue Therapeutics for Specialty Hospital Business in the U.S.

2018-11-09 08:50:01 | Fortress Biotech FBIO Reports Q3 Loss, Lags Revenue Estimates

2018-11-09 07:47:15 | Fortress Biotech: 3Q Earnings Snapshot

2018-11-09 07:30:00 | Fortress Biotech Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights